html5-img
1 / 11

BARI 2D Trial

The Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. BARI 2D Trial. Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans. Copyleft Clinical Trial Results. You Must Redistribute Slides. BARI 2D Trial: Background.

fidella
Télécharger la présentation

BARI 2D Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Bypass Angioplasty Revascularization Investigation 2 DiabetesTrial BARI 2D Trial Presented at the American Diabetes Association (ADA) Annual Scientific Sessions 2009 in New Orleans Copyleft Clinical Trial Results. You Must Redistribute Slides

  2. BARI 2D Trial: Background • Patients with Type 2 diabetes have an increased risk of suffering a cardiovascular event over non-diabetic patients. • The success of coronary revascularization in reducing myocardial infarction and death in diabetic patients with chronic stable angina has not been established. • Similarly, it is unclear if insulin sensitization therapy offers benefits over insulin provision therapy in reducing cardiovascular events. BARI 2D Study Group, NEJM 2009

  3. BARI 2D Trial: Study Design 2368 patients with mild to moderate CAD and Type 2 diabetes prior to randomization. Prospective. Randomized. Mean follow-up 5.3 years R CABG Stratum (N= 763) PCI Stratum (N= 1605) R R OMT alone (N= 385) CABG +OMT (N= 378) OMT alone (N= 807) PCI +OMT (N= 798) R R R R Provision (N= 194) Sensitization (N= 191) Provision (N= 190) Sensitization (N= 188) Provision (N= 399) Sensitization (N= 408) Provision (N= 402) Sensitization (N= 396) • Primary Endpoint: Death (from any cause) • Secondary Endpoint: Composite of Death, MI, or Stroke BARI 2D Study Group, NEJM 2009

  4. BARI 2D Trial: Baseline Characteristics Copyleft Clinical Trial Results. You Must Redistribute Slides BARI 2D Study Group, NEJM 2009

  5. BARI 2D Trial: Baseline Characteristics Copyleft Clinical Trial Results. You Must Redistribute Slides BARI 2D Study Group, NEJM 2009

  6. BARI 2D Trial: Primary Endpoint p = 0.97 • The 5-year death rate for the group receiving revascularization plus optimal medical therapy was 13.2% vs. 13.5% in the group receiving optimal medical therapy alone. • The difference between the two treatment groups did not reach statistical significance. Death (%) n =155 n =161 Copyleft Clinical Trial Results. You Must Redistribute Slides BARI 2D Study Group, NEJM 2009

  7. BARI 2D Trial: Primary Endpoint p = 0.89 • The 5-year death rate for the group receiving insulin sensitization therapy was 13.2% vs. 13.5% in the group receiving insulin provision therapy. • The difference between the two treatment groups did not reach statistical significance. Death (%) n =156 n =160 Copyleft Clinical Trial Results. You Must Redistribute Slides BARI 2D Study Group, NEJM 2009

  8. BARI 2D Trial: Secondary Endpoint • The rates of MI, stroke and the combined secondary endpoint of death, MI, and stroke were similar between the group receiving revascularization plus optimal medical therapy vs. the group receiving optimal medical therapy alone. • The difference between the two treatment groups for the combined secondary endpoint of death, MI, and stroke did not reach statistical significance (p=0.70) Cardiovascular Event (%) n=138 n=283 n=118 n=266 n=33 n=30 BARI 2D Study Group, NEJM 2009

  9. BARI 2D Trial: Secondary Endpoint • The rates of MI, stroke and the combined secondary endpoint of death, MI, and stroke were similar between the group insulin sensitization therapy vs. the group receiving insulin provision therapy. • The difference between the two treatment groups for the combined secondary endpoint of death, MI, and stroke did not reach statistical significance (p=0.13) Cardiovascular Event (%) n=138 n=288 n=118 n=261 n=36 n=27 BARI 2D Study Group, NEJM 2009

  10. BARI 2D Trial: Limitations • Patients who are at high risk for MI and, therefore, stand to benefit the most from revascularization were excluded from the trial. • The broad applicability of BARI 2D is limited by the fact that the patient population selected represents only a small subset of patients with diabetes and coronary artery disease. BARI 2D Study Group, NEJM 2009

  11. BARI 2D Trial: Summary • Neither revascularization nor optimal medical therapy demonstrated a significant reduction in the occurrence of death or major cardiovascular events at 5 years. • Likewise, there was no demonstrated difference between a strategy of insulin sensitization and insulin provision. • Further research into defining optimal medical therapy for this group of patients is needed, as evidenced by the fact that 42.1% of patients in the optimal medical therapy alone treatment group eventually required revascularization within 5 years. BARI 2D Study Group, NEJM 2009

More Related